BRISBANE, Calif., Nov. 18, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that the Company's management will be participating in two upcoming investor conferences.
CareDx is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference at The New York Palace Hotel on December 2, 2014 at 2:00pm PT/5:00pm ET. A live audio webcast of the presentation will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available on the Company's website for 90 days.
CareDx management is also scheduled to participate in the ISI MedTools Conference at the Boston Harbor Hotel in Boston, MA on December 4, 2014.
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. For more information, please visit: www.CareDxInc.com.